Back to top

Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Acorda Therapeutics (ACOR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of ACOR and the rest of the Medical group's stocks.

Acorda Therapeutics is one of 839 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ACOR is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for ACOR's full-year earnings has moved 23.94% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the latest available data, ACOR has gained about 5.71% so far this year. In comparison, Medical companies have returned an average of 4.27%. As we can see, Acorda Therapeutics is performing better than its sector in the calendar year.

Looking more specifically, ACOR belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 9.22% so far this year, so ACOR is slightly underperforming its industry this group in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on ACOR as it attempts to continue its solid performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Acorda Therapeutics, Inc. (ACOR) - free report >>

Published in